Commit Biologics has named Mikkel Wandahl Pedersen as CSO. Pedersen, with over 20 years in immuno-oncology, previously led ...

PharmaMar and Jazz Pharma positive top-line results from the Phase III clinical trial evaluating Zepzelca (lurbinectedin) in ...

Polish clinical-stage biotech Molecure has signed an exclusive licensing agreement with Ocean Biomedical based in Providence, ...

Novartis halted its Phase II IPF trial for LTP001, citing non-safety reasons. This move aligns with its strategy to ...

US clinical-stage genetic meds company MeiraGTx Holdings has released positive top-line data from its clinical bridging study ...

Johnson & Johnson (NYSE: JNJ) has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase ...

Eli Lilly (NYSE: LLY) plans to invest $206M to expand its Suzhou, China site for Type 2 diabetes and obesity drugs. The ...

Akeso Biopharma (HKEX: 9926) raised $250M via share placement, boosting cash reserves to over $1B. Funds will fast-track ...

Antibody-drug conjugates (ADCs) combine antibodies with cytotoxic drugs to target cancer cells while minimizing damage to ...

French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 ...

Almirall has completed the decentralized EU regulatory procedure for efinaconazole (Jublia) for onychomycosis. The final step ...

South Korea-based biosimilar drug developer Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) ...